Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tarrytown, New York 10591


Purpose:

This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.


Criteria:

Inclusion Criteria: 1. Completion of protocol MNTX 301; Double-Blind Treatment and Open-Label Treatment 2. Negative pregnancy test Exclusion Criteria: 1. Women who are pregnant and/or nursing 2. Any concurrent experimental drug therapy 3. Evidence of fecal impaction 4. Clinically significant active diverticular disease


NCT ID:

NCT01367600


Primary Contact:

Study Director
Tage Ramakrishna, MD
Progenics Pharmaceuticals, Inc.


Backup Contact:

N/A


Location Contact:

Tarrytown, New York 10591
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.